In Munich for its largest-ever flagship meeting, the European Society of Cardiology (ESC) Congress 2026 brought together 33,800 healthcare professionals and cardiovascular scientists from 170 countries in late August, Hospital Healthcare Europe reported. Artificial intelligence served as the spotlighted theme across cardiovascular medicine, while the four-day program simultaneously unveiled major clinical trial findings, new heart failure guidelines, and updated prevention standards.
Atorvastatin Reduces Cardiovascular Events in Older Adults Without Disability-Free Survival Benefit
The STAtins for Reducing Events in the Elderly (STAREE) trial evaluated primary prevention of cardiovascular disease using statin therapy in older populations. Presented during the congress and simultaneously published in the New England Journal of Medicine, the trial randomized 9,971 individuals aged 70 years or older without known cardiovascular disease, diabetes, or dementia to receive atorvastatin 40 mg daily or a placebo.
Over a median follow-up of 5.9 years, atorvastatin reduced the risk of major cardiovascular events by 30% compared with the placebo group. However, the therapy did not significantly improve disability-free survival. According to the American College of Cardiology coverage from ESC Congress 2026, additional prevention-focused findings included the VESALIUS-CV trial, where intensive LDL-C lowering with evolocumab in high-risk patients without prior cardiovascular events reduced major adverse cardiac events.
Transcatheter Repair and Anticoagulation Trials Address Treatment Uncertainties
Several major trials investigated interventions for structural heart disease and arrhythmias. The Tricuspid Intervention in Heart Failure (TRIC-I-HF) trial, published simultaneously in the New England Journal of Medicine, compared transcatheter tricuspid valve repair plus medical therapy against medical therapy alone in patients with severe symptomatic tricuspid regurgitation.
The SINGLE-AF trial evaluated oral anticoagulation in patients with atrial fibrillation at intermediate risk of stroke, defined by a CHA2DS2-VASc score of 1 in men and 2 in women. The study found that direct oral anticoagulant therapy reduced adverse clinical outcomes compared with no anticoagulation without significantly increasing major bleeding.
Heart Failure Terminology and Cardiac Rehabilitation Guidelines Update Clinical Frameworks
The 2026 ESC Guidelines for the management of heart failure establish revised nomenclature, introducing “foundational medical therapy” for treatments carrying a Class I recommendation to reduce hospitalization or death. The guidelines also define “additional medical therapy” and “guideline-directed interventional therapy” for device-based approaches.
For the first time, the ESC released dedicated guidelines on cardiac rehabilitation to provide a unified framework across patient groups and healthcare settings. These guidelines incorporate telehealth, telemonitoring, mobile-health apps, and wearable devices to expand home-based care access. Parallel guidelines for cardiovascular disease and chronic kidney disease (CKD), developed with the European Renal Association, emphasize wider use of kidney function and urine albumin testing to improve early detection and provide recommendations for adapting cardiovascular care in patients with CKD.
Fifth Universal Definition of Myocardial Infarction
Developed jointly by the ESC, the American College of Cardiology, the American Heart Association, and the World Heart Federation, the Fifth Universal Definition of MI was released during ESC Congress 2026.
The updated definition mandates the use of sex-specific 99th percentile upper reference limits for cardiac troponin to prevent systematic bias that can result in the under-recognition of myocardial injury and myocardial infarction in women.
Frequently Asked Questions About ESC Congress 2026 Findings
How many attendees and countries participated in ESC Congress 2026?
The Munich congress brought together 33,800 healthcare professionals and cardiovascular scientists representing 170 countries during its four-day run in late August.
What specific dosage and duration were evaluated in the STAREE trial?
The STAREE trial tested atorvastatin at 40 mg daily against a placebo in 9,971 participants aged 70 or older over a median follow-up of 5.9 years.
Which organizations partnered to release the Fifth Universal Definition of Myocardial Infarction?
The definition was developed jointly by the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.
More on European Society of Cardiology
Worth a look